Metropolis Healthcare Ltd
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
- Market Cap ₹ 8,931 Cr.
- Current Price ₹ 431
- High / Low ₹ 566 / 364
- Stock P/E 62.0
- Book Value ₹ 64.0
- Dividend Yield 0.23 %
- ROCE 13.4 %
- ROE 10.5 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 223 | 254 | 349 | 405 | 485 | 581 | 665 | 816 | 1,157 | 1,066 | 1,103 | 1,217 | 1,326 | |
| 159 | 183 | 263 | 289 | 348 | 434 | 489 | 574 | 833 | 792 | 840 | 944 | 1,025 | |
| Operating Profit | 64 | 71 | 86 | 115 | 137 | 148 | 176 | 242 | 324 | 274 | 263 | 273 | 301 |
| OPM % | 29% | 28% | 25% | 29% | 28% | 25% | 26% | 30% | 28% | 26% | 24% | 22% | 23% |
| 15 | 6 | 39 | 30 | 15 | 20 | 5 | 49 | 32 | 21 | 12 | 17 | 7 | |
| Interest | 2 | 2 | 1 | 2 | 3 | 3 | 10 | 9 | 25 | 31 | 27 | 23 | 17 |
| Depreciation | 8 | 10 | 12 | 12 | 14 | 15 | 31 | 36 | 60 | 85 | 91 | 105 | 111 |
| Profit before tax | 69 | 65 | 112 | 131 | 135 | 149 | 140 | 246 | 272 | 179 | 157 | 162 | 181 |
| Tax % | 33% | 33% | 32% | 33% | 29% | 32% | 20% | 20% | 27% | 22% | 26% | 23% | |
| 46 | 43 | 76 | 88 | 96 | 101 | 112 | 198 | 200 | 139 | 116 | 125 | 138 | |
| EPS in Rs | 11.77 | 10.90 | 19.88 | 23.04 | 25.07 | 5.06 | 5.53 | 9.66 | 9.75 | 6.78 | 5.66 | 6.02 | 6.67 |
| Dividend Payout % | 3% | 0% | 101% | 57% | 0% | 66% | 36% | 21% | 21% | 29% | 18% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -2% |
| 3 Years: | -14% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | 12% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 17% |
| 3 Years: | 12% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 254 | 296 | 233 | 258 | 354 | 405 | 502 | 699 | 829 | 926 | 1,021 | 1,234 | 1,317 |
| 16 | 10 | 4 | 0 | 0 | 17 | 54 | 85 | 377 | 268 | 195 | 178 | 152 | |
| 33 | 35 | 95 | 170 | 76 | 95 | 122 | 140 | 242 | 230 | 247 | 262 | 252 | |
| Total Liabilities | 313 | 351 | 341 | 438 | 440 | 528 | 688 | 933 | 1,459 | 1,434 | 1,473 | 1,685 | 1,732 |
| 83 | 84 | 92 | 152 | 157 | 163 | 216 | 251 | 1,005 | 1,066 | 1,120 | 1,129 | 1,110 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 | 0 |
| Investments | 148 | 175 | 120 | 143 | 98 | 135 | 130 | 131 | 50 | 50 | 90 | 321 | 362 |
| 82 | 92 | 129 | 143 | 185 | 224 | 340 | 552 | 398 | 299 | 263 | 235 | 259 | |
| Total Assets | 313 | 351 | 341 | 438 | 440 | 528 | 688 | 933 | 1,459 | 1,434 | 1,473 | 1,685 | 1,732 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52 | 43 | 75 | 77 | 74 | 56 | 156 | 202 | 244 | 238 | 269 | 275 | |
| -39 | -36 | 101 | -67 | 19 | -4 | -51 | 74 | -736 | 47 | -82 | -196 | |
| -10 | -10 | -165 | -17 | -82 | -64 | -46 | -26 | 172 | -288 | -183 | -84 | |
| Net Cash Flow | 3 | -3 | 11 | -6 | 12 | -12 | 59 | 250 | -320 | -3 | 4 | -6 |
| Free Cash Flow | 42 | 30 | 65 | 65 | 59 | 37 | 133 | 178 | 207 | 189 | 209 | 213 |
| CFO/OP | 112% | 91% | 122% | 100% | 88% | 73% | 116% | 103% | 99% | 103% | 112% | 113% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 60 | 50 | 56 | 62 | 74 | 68 | 55 | 44 | 43 | 43 | 34 |
| Inventory Days | 49 | 50 | 42 | 35 | 49 | 52 | 38 | 57 | 66 | 64 | 56 | 47 |
| Days Payable | 64 | 71 | 84 | 93 | 87 | 95 | 155 | 155 | 131 | 133 | 155 | 160 |
| Cash Conversion Cycle | 34 | 38 | 7 | -1 | 24 | 31 | -48 | -42 | -22 | -26 | -55 | -79 |
| Working Capital Days | 60 | 48 | 12 | -47 | 43 | 47 | 20 | 10 | -20 | -15 | -15 | -24 |
| ROCE % | 22% | 37% | 50% | 43% | 38% | 35% | 37% | 28% | 17% | 15% | 13% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratories Number |
|
|||||||||
| Number of Patient Visits (Millions) Millions |
||||||||||
| Number of Tests Conducted (Millions) Millions |
||||||||||
| Service Network points (Collection Centers/PSCs/ARCs) Number |
||||||||||
| Revenue Per Patient (RPP) INR |
||||||||||
Documents
Announcements
-
Business Update For Q4FY26
3 Apr - Q4FY26 business update: consolidated revenue up ~23% YoY; organic revenue up ~14.5%.
- Closure of Trading Window 31 Mar
-
Announcement under Regulation 30 (LODR)-Allotment
23 Mar - Allotted 15,54,95,826 bonus shares (3:1) on March 23, 2026; new share count 20,73,27,768; paid-up capital INR 41,46,55,536.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Mar - Group analyst/institutional investor meeting March 25, 2026 at 03:00 PM IST; only publicly available information to be discussed.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Mar
Annual reports
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptAI SummaryPPT
-
Sep 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019Transcript PPT
Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.